Media stories about Prothena (NASDAQ:PRTA) have trended somewhat negative this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Prothena earned a coverage optimism score of -0.05 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.5617009815369 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Woodford-backed Prothena dealt fresh blow after exit (citywire.co.uk)
- Keep Your Active Eyes on Prothena Corporation plc (PRTA) with Unusual Volume Alert – Wall Street Morning (wallstreetmorning.com)
- Prothena to Participate in the Leerink Partners 7th Annual Global … – GlobeNewswire (press release) (globenewswire.com)
- Prothena to Participate in the Leerink Partners 7th Annual Global Healthcare Conference (finance.yahoo.com)
- Investors Buy Large Volume of Call Options on Prothena (PRTA) (americanbankingnews.com)
Several equities analysts have recently issued reports on the stock. BidaskClub raised shares of Prothena from a “strong sell” rating to a “sell” rating in a report on Thursday, January 11th. ValuEngine downgraded shares of Prothena from a “sell” rating to a “strong sell” rating in a report on Wednesday. Zacks Investment Research downgraded shares of Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Wedbush downgraded shares of Prothena from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $75.00 to $55.00 in a report on Monday, November 20th. Finally, Oppenheimer reissued a “buy” rating and set a $70.00 price target on shares of Prothena in a report on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $75.58.
Shares of Prothena (NASDAQ PRTA) traded up $0.24 during midday trading on Friday, hitting $28.19. 982,723 shares of the company were exchanged, compared to its average volume of 682,906. Prothena has a fifty-two week low of $27.19 and a fifty-two week high of $70.00. The company has a market capitalization of $1,083.82, a PE ratio of -6.66 and a beta of 2.67.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.